Release date: December 3, 2006
Relview date: October 24, 2007
Available for credit through: December 31, 2008
Program Description
Despite data showing the positive impact of treating febrile neutropenia and anemia in chemotherapy patients, a majority of patients still do not receive proper treatment. The European Cancer Anemia Survey (ECAS) reported that over 60% of the cancer-associated anemia patients did not receive any treatment for their anemia. Moreover, approximately 60,000 cancer patients are hospitalized annually with febrile neutropenia in the United States. This program will address strategies for treating chemotherapy induced anemia and febrile neutropenia, including identifying patients at risk and available treatment agents. Additionally, a review of the updated practice guidelines from ASCO, NCCN and EORTC and their practical applications will be discussed.
Target Audience
This program is of interest to pharmacists involved in the management of chemotherapy patients.
Educational Objectives
At the conclusion of this activity, clinical pharmacists will be able to:
Describe the risk factors associated with febrile neutropenia and anemia
Differentiate the various recombinant hematopoetic growth factors available for treatment of febrile neutropenia and cancer-induced anemia
Identify patients that may benefit from hematopoetic growth factor therapy
Evaluate the recent change in NCCN, ASCO, and EORTC guidelines as they apply to cancer-induced febrile neutropenia and anemia
There are no fees to participate in this activity. A certificate of completion for physicians and a statement of credit for pharmacists may be printed out after viewing the program and submitting your post-test and evaluation form.
Accreditation
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. (Course UPN 200-000-06-025-H01-P). Pharmacists will receive 1 contact hour upon completion of this activity.
Faculty Disclosure Declarations
Dwight Kloth, PharmD, FCCP, BCOP – Advisory Board or Review Panel Member and Speakers' Bureau- Amgen and MGI Pharma; Advisory Board – Sanofi-Aventis
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Amgen, any other manufacturer of pharmaceuticals, or ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. (Course UPN 200-000-06-025-H01-P). Pharmacists will receive 1 contact hour upon completion of this activity.